Suriya reuniting with Sudha Kongara for new movie; Dulquer, Nazriya and Vijay Varma to also star
Chennai (PTI): Actor Suriya on Thursday announced that he is teaming up with his "Soorarai Pottru" director Sudha Kongara for a new feature film.
The movie, which will be Suriya's 43rd project, will also star Dulquer Salmaan, Nazriya Nazim Fahadh and Vijay Varma.
"Dear all we are excited! Joining hands with @Sudha_Kongara again in a @gvprakash musical, his 100th! So looking forward to work with my brother @dulQuer & the talented #Nazriya & the performance champ @MrVijayVarma. Glad @2D_ENTPVTLTD
is producing this special film! #Jyotika @rajsekarpandian #Suriya43," Suriya posted on X.
Ace composer GV Prakash Kumar will provide the music for the film, which marks his 100th project as a music director.
Suriya's production banner 2D Entertainment, which he heads with actor-wife Jyotika, also shared the news on X.
"Rustic. Powerful. Strong @Suriya_offl @dulQuer #Nazriya @MrVijayVarma in #Suriya43. A film by @Sudha_Kongara. A @gvprakash Musical," the banner posted.
Suriya and Kongara's 2020 Tamil film "Soorarai Pottru" had won five National Awards, including best actor and best feature film.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
New study reveals adverse events in some covaxin recipients
New Delhi: A recent study conducted by Sankha Shubhra Chakrabarti and his team at Banaras Hindu University has shed light on adverse events observed in participants who received Covaxin, Bharat Biotech's COVID-19 vaccine.
The study involved 1,024 individuals, comprising 635 adolescents and 291 adults, who were followed up for one year after receiving Covaxin.
Nearly a third of the participants reported adverse events of special interest (AESI) during the observation period. These included viral upper respiratory tract infections, new-onset skin and subcutaneous disorders, general disorders, nervous system disorders, menstrual abnormalities in females, ocular abnormalities, and hypothyroidism.
The study identified several risk factors associated with AESI. Female adolescents and individuals with a history of allergies were found to be at higher risk. Additionally, participants with pre-vaccination COVID-19, comorbidities, and post-vaccination typhoid were also identified as having increased risk.
A significant number of AESIs persisted even at the 1-year follow-up. Female individuals, adolescents with pre-vaccination COVID-19, those with comorbidities, and those with post-vaccination typhoid had higher odds of persistent AESIs.
Among serious adverse events, stroke and Guillain-Barre Syndrome were identified in a small percentage of participants.
The study highlights the importance of extended surveillance of COVID-19 vaccinated individuals to understand the course and outcomes of late-onset adverse events. Focused monitoring for persistent AESIs is recommended, especially for individuals with certain risk factors.
The findings suggest that the patterns of adverse events observed with Covaxin differ from those reported with other COVID-19 vaccines. Understanding these patterns is crucial for effective post-vaccination monitoring and management of potential risks.
